retatrutide triple agonist gip glp-1 glucagon phase 2 obesity trial 40mg Unapproved weight loss drug retatrutide
Description
Placebo-subtracted weight loss achieved by Qsymia is typically in the range of 510% after up to 56 wk of treatment [904,905]
Andersen A, Lund A
Meta-analyses have confirmed the benefit of GLP-1 RAs as a class in both secondary and primary prevention of cardiovascular disease, and in reduction of adverse kidney outcomes in people with T2D (Kristiensen et al, 2019
Nature 499 , 438443 (2013) Siu, F
